Science and Research

BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells

BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrol idin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which qualifies this molecule as a good in vitro and in vivo tool compound. BI 1002494 exhibits higher potency in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation (IC50 = 115 nM) compared with B-cell receptor-mediated activation of B cells (IC50 = 810 nM). This may be explained by lower kinase potency when the physiologic ligand B-cell linker was used, suggesting that SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand. A 3-fold decrease in potency was observed in rat basophils (IC50 = 323 nM) compared with human basophils, but a similar species potency shift was not observed in B cells. The lower potency in rat basophils was confirmed in both ex vivo inhibition of bronchoconstriction in precision-cut rat lung slices and in reversal of anaphylaxis-driven airway resistance in rats. The different cellular potencies translated into different in vivo efficacy; full efficacy in a rat ovalbumin model (that contains an element of mast cell dependence) was achieved with a trough plasma concentration of 340 nM, whereas full efficacy in a rat collagen-induced arthritis model (that contains an element of B-cell dependence) was achieved with a trough plasma concentration of 1400 nM. Taken together, these data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated.

  • Lamb, D. J.; Wollin, S. L.; Schnapp, A.; Bischoff, D.; Erb, K. J.; Bouyssou, T.; Guilliard, B.; Strasser, C.; Wex, E.; Blum, S.; Thaler, E.; Nickel, H.; Radmacher, O.; Haas, H.; Swantek, J. L.; Souza, D.; Canfield, M.; White, D.; Panzenbeck, M.; Kashem, M. A.; Sanville-Ross, M.; Kono, T.; Sewald, K.; Braun, A.; Obernolte, H.; Danov, O.; Schaenzle, G.; Rast, G.; Maier, G. M.; Hoffmann, M.

Keywords

  • Administration, Oral
  • Animals
  • B-Lymphocytes/*drug effects/*enzymology
  • Basophils/*drug effects/*enzymology
  • Humans
  • Male
  • Mast Cells/drug effects/enzymology
  • Naphthyridines/administration & dosage/*pharmacology
  • Protein Kinase Inhibitors/administration & dosage/*pharmacology
  • Pyrrolidines/administration & dosage/*pharmacology
  • Pyrrolidinones/administration & dosage/*pharmacology
  • Rats
  • Syk Kinase/*antagonists & inhibitors
Publication details
DOI: 10.1124/jpet.116.233155
Journal: The Journal of pharmacology and experimental therapeutics
Pages: 554-61 
Number: 3
Work Type: Original
Location: BREATH
Disease Area: AA
Partner / Member: ITEM
Access-Number: 27048659
See publication on PubMed


chevron-down